Remyelination News and Research RSS Feed - Remyelination News and Research

Remyelination is a term for the re-generation of the nerve's myelin sheath, damaged in many diseases such as multiple sclerosis (MS) and the leukodystrophies. Remyelination is a subject of active medical research.
Researchers identify genetic risk factor for binge eating

Researchers identify genetic risk factor for binge eating

Researchers have identified a gene (CYFIP2) associated with binge eating. This finding represents one of the first examples of a genome-wide significant genetic factor to be identified for binge eating in model organisms or humans. [More]
Clinical trial assesses efficacy of experimental treatment in individuals with cervical spinal cord injury

Clinical trial assesses efficacy of experimental treatment in individuals with cervical spinal cord injury

Physicians at Rush University Medical Center became the first in Illinois to inject AST-OPC1 (oligodendrocyte progenitor cells), an experimental treatment, into the damaged cervical spine of a recently paralyzed man as part of a multicenter clinical trial. [More]
Cell therapy product can accelerate brain remyelination in mice

Cell therapy product can accelerate brain remyelination in mice

Demyelinating diseases, such as multiple sclerosis and leukodystrophy, are characterized by damage to the protective myelin sheath that surrounds the axons of neurons. [More]
Innovations in pre-clinical MRI: an interview with Priv. Doz. Dr. Dominik von Elverfeldt

Innovations in pre-clinical MRI: an interview with Priv. Doz. Dr. Dominik von Elverfeldt

To me the most exciting aspect of pre-clinical imaging is its broad range, from very basic science up to applied science. You deal with a range of disciplines including biology, chemistry, physics, biochemistry, biophysics, cell biology and of course medicine, as the aim is the translation of research to humans. [More]
Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Novoron Bioscience, Inc., a private biotech company dedicated to developing new therapeutics for disorders of the central nervous system, today announced that the company has been awarded a National Institutes of Health grant under the Small Business Innovation Research (SBIR) Program. [More]
Asterias’ Phase 1/2a study evaluates dose escalation of AST-OPC1 for cervical spinal cord injury

Asterias’ Phase 1/2a study evaluates dose escalation of AST-OPC1 for cervical spinal cord injury

Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company focused on the emerging field of regenerative medicine, today announced that its Data Monitoring Committee has reviewed the initial safety data from all three patients in the first cohort and has recommended dose escalation to the second cohort. [More]
Experimental drug shows promise in mice with multiple sclerosis

Experimental drug shows promise in mice with multiple sclerosis

An experimental drug originally identified in a National Cancer Institute library of chemical compounds as a potential therapy for brain and basal cell cancers improves the symptoms of mice with a form of the debilitating neurological disorder multiple sclerosis (MS), according to new research from NYU Langone Medical Center. [More]
Researchers reveal molecular mechanism that controls remyelination

Researchers reveal molecular mechanism that controls remyelination

Researchers in Japan have revealed the molecular mechanism involved in the process of repair to damage of the myelin sheath. In vertebrates, axons extending from nerve cells are covered by insulating sheets called the myelin sheath, made with the cell membranes of oligodendrocytes, enabling fast electrical signaling through saltatory conduction. [More]
Several drugs could lead to new MS treatment options

Several drugs could lead to new MS treatment options

New research published this week in Nature has found several drugs could lead to new treatment options for multiple sclerosis (MS), including two drugs that effectively treat MS at the source, in vivo. When administered at the peak of disease, these two drugs showed a striking reversal of disease severity. [More]
Two existing drugs may potentially become new drug target for multiple sclerosis

Two existing drugs may potentially become new drug target for multiple sclerosis

Two drugs already on the market -- an antifungal and a steroid -- may potentially take on new roles as treatments for multiple sclerosis. According to a study published in Nature today, researchers discovered that these drugs may activate stem cells in the brain to stimulate myelin producing cells and repair white matter, which is damaged in multiple sclerosis. [More]
New longer-term data on Genzyme's relapsing MS treatments to be presented at AAN 2015

New longer-term data on Genzyme's relapsing MS treatments to be presented at AAN 2015

Genzyme, a Sanofi company, announced today that new longer-term data on its relapsing multiple sclerosis treatments, Aubagio (teriflunomide) and Lemtrada (alemtuzumab), will be featured during the 67th annual meeting of the American Academy of Neurology being held in Washington, D.C. April 18-25. [More]
Existing drug could help treat MS, other neurological diseases

Existing drug could help treat MS, other neurological diseases

Damage to myelin, the fatty insulator that enables communication between nerve cells, characterizes multiple sclerosis (MS) and other devastating neurological diseases. [More]
Ligand indazole chloride improves motor function, study shows

Ligand indazole chloride improves motor function, study shows

Multiple sclerosis (MS), an autoimmune disease of the brain and spinal cord, affects about 2.3 million people worldwide (400,000 in the United States). Affecting more women than men, it can be seen at any age, although it is most commonly diagnosed between the ages of 20 and 40. [More]
Asterias, CIRM sign NGA to begin AST-OPC1 study for complete cervical spinal cord injury

Asterias, CIRM sign NGA to begin AST-OPC1 study for complete cervical spinal cord injury

Asterias Biotherapeutics, Inc. announced today that the Company has signed a Notice of Grant Award (NGA) with the California Institute of Regenerative Medicine (CIRM), effective October 1, 2014. [More]
Cell transplantation treatment may benefit people with spinal cord injury

Cell transplantation treatment may benefit people with spinal cord injury

Two studies recently published in Cell Transplantation reveal that cell transplantation may be an effective treatment for spinal cord injury (SCI), a major cause of disability and paralysis with no current restorative therapies. [More]
New MS treatment found safe, tolerable in phase I clinical trials

New MS treatment found safe, tolerable in phase I clinical trials

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology Neuroimmunology & Neuroinflammation, a new online-only, freely accessible, specialty medical journal. [More]
Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias Biotherapeutics Inc. has received clearance from the U.S. Food and Drug Administration to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury. [More]
Neuregulin 1 effective in promoting peripheral nerve regrowth

Neuregulin 1 effective in promoting peripheral nerve regrowth

Neuregulin 1 (NRG1) is a pleiotropic factor characterized by the existence of numerous isoforms arising from alternative splicing of exons that confer to the protein deeply different characteristics. [More]
Researchers identify protein that promotes growth of brain cells damaged by MS

Researchers identify protein that promotes growth of brain cells damaged by MS

Vittorio Gallo, PhD, Director of the Center for Neuroscience Research at Children's National Health System, and other researchers have found a "potentially novel therapeutic target" to reduce the rate of deterioration and to promote growth of brain cells damaged by multiple sclerosis (MS). Current therapies can be effective in patients with relapsing MS, but have little impact in promoting tissue growth. [More]
LA BioMed receives grant to study role of serum Vitamin A in people with multiple sclerosis

LA BioMed receives grant to study role of serum Vitamin A in people with multiple sclerosis

Some 2.5 million people around the world have multiple sclerosis (MS), a potentially debilitating disease in which the body's immune system destroys the protective sheath (myelin) that covers nerves. [More]
Advertisement
Advertisement